RESOLVE TO PRESENT DATA ON LUPUS STUDIES AT INTERNATIONAL RHEUMATOLOGY CONFERENCE

Seattle, WA- (May 26, 2016) Resolve Therapeutics, LLC, a clinical stage biopharmaceutical company developing potentially transformative therapies for the treatment of lupus and Sjogrens syndrome, today announced it will be presenting data from two clinical studies at the EULAR Annual European Congress of Rheumatology to be held in London, June 8-11.

Dr. Keith Elkon, Resolve’s scientific founder will be delivering an oral presentation entitled, “Immune Complex Bound U1 and Y1 RNA Correlates With Interferon-Stimulated Gene Expression and Disease Activity: An Observational Study of Systemic Lupus Erythematosus Patients.” Dr. Elkon will give the presentation on June 10th at 10:50.

Dr. James Posada, Resolve’s founder and CEO will present the results of a recently completed phase 1b clinical trial with its lead compound, RSLV-132. The presentation is entitled “Safety, Pharmacokinetics, and Pharmacodynamics of RSLV-132, a Novel RNase-Fc Fusion Protein Developed to Reduce RNA-Containing Immune Complexes in Systemic Lupus Erythematosus.” Dr. Posada will give the presentation on June 9th at 11:45.

About Resolve Therapeutics
Resolve Therapeutics is a privately held biotechnology company that is dedicated to helping patients with lupus and Sjogrens syndrome through the development of its platform of targeted nuclease therapeutics. In addition to the lead molecule, RSLV-132,
the company is developing additional molecules that contain both RNase and DNase activities, which may also be useful in the treatment of lupus, Sjogrens syndrome and other autoimmune diseases. Resolve is funded by a syndicate of venture capital firms including, New Science Ventures, WRF Capital, and Easton Capital. For more information on the company please visit: [http://www.resolvebio.com](http://www.resolvebio.com).

Contact:
James Posada, Ph.D.
Chief Executive Officer
Resolve Therapeutics, LLC
(208) 727-7010
jp@resolvebio.com